Clinical TrialJun 16, 2026, 07:33 AM
Clearmind Completes Dosing for 24 Participants in CMND-100 Trial Part A
AI Summary
Clearmind Medicine Inc. announced the successful completion of dosing for all 24 participants in Cohorts 1 through 4 of Part A of its ongoing Phase I/II clinical trial. The trial is evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD). Interim results from the first three cohorts continue to show a strong safety profile, and the trial is being conducted under FDA oversight at leading clinical sites.
Key Highlights
- Completed dosing for all 24 participants in Cohorts 1-4 of Part A of the Phase I/II clinical trial.
- The trial evaluates CMND-100 for the treatment of Alcohol Use Disorder (AUD).
- Interim results from the first three cohorts show a strong safety profile.
- Trial sites include Yale, Johns Hopkins, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.
- The study is a multicenter, randomized, double-blind, placebo-controlled trial under FDA oversight.
Price Impact
More from CMND